Do rheumatoid arthritis patients have equal access to treatment with new medicines?: tumour necrosis factor-alpha inhibitors use in four European countries.

[1]  E. Nolte,et al.  International Variation in the Usage of Medicines: A Review of the Literature. , 2010, Rand health quarterly.

[2]  Laure Gossec,et al.  Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis , 2010, Annals of the rheumatic diseases.

[3]  John Wong,et al.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs , 2010, Annals of the rheumatic diseases.

[4]  J. Jacobs,et al.  Adverse events and factors associated with toxicity in patients with early rheumatoid arthritis treated with methotrexate tight control therapy: the CAMERA study , 2009, Annals of the rheumatic diseases.

[5]  H. Leufkens,et al.  Variable access to clopidogrel in a harmonized EU market. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[6]  W. Koldingsnes,et al.  The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. , 2008, Arthritis and rheumatism.

[7]  H. H. Kuper,et al.  The effectiveness and medication costs of three anti-tumour necrosis factor α agents in the treatment of rheumatoid arthritis from prospective clinical practice data , 2007, Annals of the rheumatic diseases.

[8]  F. Pucino,et al.  Use of biologics in rheumatoid arthritis: where are we going? , 2006, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[9]  J. O'dell,et al.  Therapeutic strategies for rheumatoid arthritis. , 2004, The New England journal of medicine.

[10]  J. Smolen,et al.  Therapeutic strategies for rheumatoid arthritis , 2003, Nature Reviews Drug Discovery.

[11]  E. Skovlund,et al.  Problems in collecting comparable national drug use data in Europe: the example of antibacterials , 2003, European Journal of Clinical Pharmacology.

[12]  P. Emery,et al.  Treating rheumatoid arthritis with tumour necrosis factor α blockade , 2002, BMJ : British Medical Journal.

[13]  P. Hannonen,et al.  Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial , 1999, The Lancet.

[14]  J. Branco,et al.  Portuguese guidelines for the use of biological agents in rheumatoid arthritis - March 2010 update. , 2010, Acta reumatologica portuguesa.

[15]  S SmolenJosef,et al.  EULAR (欧州リウマチ学会) 合成および疾患修飾性抗リウマチ生物学的製剤による関節リウマチ管理に関する推奨ガイドライン | 文献情報 | J-GLOBAL 科学技術総合リンクセンター , 2010 .

[16]  E. Nolte,et al.  International variation in the usage of medicines , 2010 .

[17]  S. Berney.  Comparison of Treatment Strategies in Early Rheumatoid Arthritis: A Randomized Trial , 2008 .

[18]  B. Jönsson,et al.  The burden of rheumatoid arthritis and access to treatment: uptake of new therapies , 2007, The European Journal of Health Economics.

[19]  Portuguese guidelines for the use of biological agents in rheumatoid arthritis--December 2007 update. , 2007, Acta reumatologica portuguesa.

[20]  Christine Y. Lu,et al.  Recent developments in targeting access to high cost medicines in Australia , 2005, Australia and New Zealand health policy.